Therapeutic Potential of IL‐37 in Cervical Cancer: Suppression of Tumour Progression and Enhancement of CD47‐Mediated Macrophage Phagocytosis

Yuan Feng,Lianlian Feng,Bingyu Wang,Teng Zhang,Baoxia Cui

DOI: https://doi.org/10.1002/mc.23855

2024-12-04

Molecular Carcinogenesis

Abstract:As a promising therapeutic approach, immunotherapy is being extensively investigated in cervical cancer. Although immunotherapy has been validated to improve progression‐free survival and overall survival in clinical trials, the overall response rate for cervical cancer remains inadequate, necessitating further improvement. Interleukin (IL)‐37, an emerging immunomodulator, exhibits antitumour potentials by inhibiting tumour progression and regulating tumour‐associated macrophage recognition. We found a significant downregulation of IL‐37 expression in cervical cancer, correlated with a poor prognosis. Moreover, the upregulation of IL‐37 expression exhibited a suppressive effect on various tumorigenic processes, suppressing the proliferation, invasion, migration, apoptosis and angiogenesis of tumour cells. We also found that the upregulation of IL‐37 suppressed cluster of differentiation 47 (CD47) expression in tumour cells via suppression of the signal transducer and activator of transcription 3 (STAT3) expression and phosphorylation, thereby enhancing macrophage recognition and phagocytosis to tumour cells, ultimately reducing immune evasion. Overall, our study highlighted the crucial role of IL‐37 in antitumour efficacy and downregulating the expression of CD47 in tumour cells to reduce immune evasion, suggesting the potential of IL‐37 as a prognostic biomarker in cervical cancer and offering innovative therapeutic strategies to improve cancer treatment outcomes.

oncology,biochemistry & molecular biology